Edwards Lifesciences (EW) Tops Q2 EPS by 5c; offers guidance

Edwards Lifesciences (NYSE: EW) reported Q2 EPS of $0.67, $0.05 better than the analyst estimate of $0.62. Revenue for the quarter came in at $1.53 billion versus the consensus estimate of $1.49 billion.

GUIDANCE:

Edwards Lifesciences sees FY2025 EPS of $2.40-$2.50, versus the consensus of $2.47.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.

You May Also Be Interested In

• Trump on Iran: we're trying to work out a deal that's fair
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Backblaze (BLZE) call put ratio 12.9 calls to 1 put with a focus on July 12.50 calls as share price up 40%